Novartis updates US label on Gilenya® following discussions with the FDA
(Thomson Reuters ONE) -
Novartis International AG /
Novartis updates US label on Gilenya® following discussions with the FDA
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Updated Gilenya label provides further guidance to healthcare providers
regarding treatment initiation with Gilenya in MS patients in the United
States
* Prescribing information includes patient selection parameters to aid in the
identification of candidates for Gilenya treatment
* Update to label marks the conclusion of discussions initiated in December
2011
Basel, April 20, 2012 - Novartis announced today agreement with the US Food and
Drug Administration (FDA) on label changes for Gilenya® (fingolimod).
The update to the Gilenya prescribing information includes patient selection
parameters to aid in the identification of candidates for Gilenya treatment and
more specific recommendations for treatment initiation for patients with
relapsing forms of MS in the United States. The update marks the conclusion of
discussions initiated in December 2011.
The updated FDA label for Gilenya indicates that all patients initiating
treatment with Gilenya should have an electrocardiogram (ECG) prior to the first
dose of the medicine and after the six-hour first-dose observation period in
addition to hourly measurement of blood pressure and heart rate. Additionally,
specific initiation guidance for patients is now provided to better aid
healthcare providers. Further, there are revised recommendations on how to re-
initiate therapy should Gilenya be interrupted.
As of February 2012, approximately 36,000 patients have been treated with
Gilenya in clinical trials and in the post-marketing setting.
"Gilenya represents an important treatment option for relapsing forms of MS,"
said Dr. Barry Singer, Director, MS Center for Innovations in Care, Missouri
Baptist Medical Center. "Choosing appropriate patients for Gilenya therapy and
patient safety is essential."
If therapy is interrupted for patients who are already taking Gilenya, they
should undergo the new recommended monitoring upon treatment re-initiation as
per the revised recommendations on the duration of interruption depending on
duration of prior treatment. Patients should not make any changes to any
medications they are taking, including Gilenya, without consulting their doctor.
The label update in the US for Gilenya recommends that patients with certain
pre-existing cardiac conditions or those taking certain concomitant medications
would require overnight monitoring following administration of first dose of
medication, and for some patients prior evaluation with a specialist. Experience
with the use of Gilenya in such patients was limited in the pivotal clinical
trials.
Gilenya is contraindicated in patients with history or presence of certain
cardiac conditions, including heart attack or stroke in the past six months,
second- and third-degree AV block and other serious cardiac rhythm disturbances,
and in patients treated with certain anti-arrhythmic drugs.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "recommendations," "believe," "recommends," or similar
expressions, or by express or implied discussions regarding potential future
revenues from Gilenya. You should not place undue reliance on these statements.
Such forward-looking statements reflect the current views of management
regarding future events, and involve known and unknown risks, uncertainties and
other factors that may cause actual results with Gilenya to be materially
different from any future results, performance or achievements expressed or
implied by such statements. There can be no guarantee that Gilenya will achieve
any particular levels of revenue in the future. In particular, management's
expectations regarding Gilenya could be affected by, among other things,
unexpected regulatory actions or delays or government regulation generally,
including the finalization of EU review of the Gilenya label; unexpected
clinical trial results, including unexpected new clinical data and unexpected
additional analysis of existing clinical data; competition in general;
government, industry and general public pricing pressures; unexpected
manufacturing issues; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection; the impact that the
foregoing factors could have on the values attributed to the Novartis Group's
assets and liabilities as recorded in the Group's consolidated balance sheet,
and other risks and factors referred to in Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2011, the Group's
continuing operations achieved net sales of USD 58.6 billion, while
approximately USD 9.6 billion (USD 9.2 billion excluding impairment and
amortization charges) was invested in R&D throughout the Group. Novartis Group
companies employ approximately 124,000 full-time-equivalent associates and
operate in more than 140 countries around the world. For more information,
please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Julie Morrow
Novartis Global Media Relations Novartis Pharma Communications
+41 61 324 7999 (direct) +41 61 696 7581 (direct)
+41 79 593 4202 (mobile) +41 79 357 3259 (mobile)
eric.althoff(at)novartis.com julie.morrow(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Susanne Schaffert +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Helen Boudreau +1 212 830 2404
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1604414/507624.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1604414]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2012 - 08:01 Uhr
Sprache: Deutsch
News-ID 1105468
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Basel
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 160 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis updates US label on Gilenya® following discussions with the FDA
"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
